• margaret

    Cancer patients want their data to be shared for research

    Margaret Grayson*, a breast cancer survivor in Northern Ireland, explains why sharing cancer patient data for ethical medical research is so important for the benefit of future patients.


    *National Cancer Intelligence Network Conference, Belfast, June 2015

  • Mendelian randomization - Richard Martin

    Mendelian randomisation

    Prof Richard Martin, Head of Clinical Epidemiology and Public Health at the University of Bristol, and his colleague, Dr Philip Haycock, spoke on Mendelian randomisation at LSHTM in January 2016.

    To find out more, click on the title and check out the video recording posted on our News page.

  • Cancer Survival Short Course group photo (slider)

    Cancer Survival: Principles, Methods and Applications

    27 June – 1 July 2016


    We are now accepting applications for the 2016 course on Cancer Survival: Principles, Methods and Applications.

  • cancer test

    Tools for Analysis

    You can register for access to our cancer survival analysis tools, including the CONCORD life tables, here.


    Mexhaz, Strel, ewblft programs and the CONCORD life tables are copyright to the London School of Hygiene & Tropical Medicine.

  • worldmappurple

    World Map

    Our interactive map will soon be available for public access. A great way to find out more about our projects.


    You can find it under the Research tab or here.

Our research is designed to explain trends and inequalities in cancer survival at regional, national and international level, including in socio-economic, racial and ethnic groups of the population. The results help policy-makers to target investment in cancer services to improve survival and reduce inequalities. The core target in the national cancer plan for England – to reduce avoidable cancer deaths by 5,000 a year, is based on our research comparing survival trends in Britain with trends in other European countries. We also develop new methods for cancer survival analysis, as part of the CENSUR group.

Socio-economic inequalities in cancer survival in England have fallen only slightly since the NHS Cancer Plan of 2000: this has important policy implications for earlier diagnosis and more rapid access to optimal treatment for all groups of society. The EUROCARE-5 study showed that survival for cancer patients diagnosed up to 2007 in the UK has remained lower than in many other European countries, although the differences are becoming less marked for some cancers. We have reported regional differences in survival within the UK. In collaboration with 279 cancer registries, we recently reported huge world-wide differences in cancer survival among over 25 million cancer patients in 67 countries (CONCORD-2).

We are now on Twitter. Our research publications are here. Our statistical software and other tools for cancer survival analysis are available free here.

Our annual short course on Cancer Survival: Principles, Methods and Applications has been running for ten years: details for 2015 here. Participants based in low-, lower-middle and upper-middle income countries [LMIC] are entitled to a special discounted fee.

onslogo_tcm77-255948Together with the Office for National Statistics (ONS), we have published the official National Statistics on cancer survival in England every year since 2000, as well as the NHS Outcome Framework indicators on cancer survival for the 211 Clinical Commissioning Groups. We recently published survival figures for all childhood cancers combined.

014AAA96-C183-C972-941F3897002D913AWe have shown that half of all people diagnosed in England and Wales can now expect to survive from their cancer for at least 10 years, compared to just 25% 40 years ago. Cancer Research UK launched its new research strategy in 2014 on the basis of these results. For more information please follow this link.

Comments are closed.